Publikationen

Development of the first geldanamycin-based HSP90 degraders
Wurnig, Silas; Vogt, Melina; Hogenkamp, Julian; Dienstbier, Niklas; Borkhardt, Arndt; Bhatia, Sanil; Hansen, Finn (2023-06-28)
Despite the early clinical promise, adverse events such as acquired resistance and dose-limiting toxicities have barred the widespread use of HSP90 inhibitors as anticancer drugs. A new approach involving proteolysis-targeting ...
A Systematic Database Approach to Identify Companion Diagnostic Testing in Clinical Trials under the New In Vitro Diagnostic Medical Devices Regulation
Wollenhaupt, Clara; Sudhop, Thomas; Knoess, Werner (2023-06-12)
The European Union In Vitro Diagnostic Medical Devices Regulation (EU) 2017/746 (IVDR) introduces companion diagnostics (CDx) as a new legal term. CDx are applied in combination with a medicinal product to identify patient ...
Irreversible Antagonists for the Adenosine A2B Receptor
Temirak, Ahmed; Schlegel, Jonathan; Voss, Jan; Vaaßen, Victoria; Vielmuth, Christin; Claff, Tobias; Müller, Christa (2022-06-13)
Blockade of the adenosine A2B receptor (A2BAR) represents a potential novel strategy for the immunotherapy of cancer. In the present study, we designed, synthesized, and characterized irreversible A2BAR antagonists based ...

Pharmazeutisches Institut: Publikationen